PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Urology/Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 405 30, Gothenburg, Sweden. karin.welen@gu.se.\', \'Department of Clinical Microbiology, Section of Virology, Umeå University, Umeå, Sweden.\', \'Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden.\', \'Department of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden.\', \'Department of Medical Sciences, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.\', \'Department of Urology, Region of Jönköping, Jönköping, Sweden.\', \'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.\', \'Department of Clinical Microbiology, Region Jönköping County, Jönköping, Sweden.\', \'Department of Urology/Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 405 30, Gothenburg, Sweden.\', \'Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.\', \'Department of Surgical and Perioperative Sciences, Urology & Andrology, Umeå University, 901 87, Umeå, Sweden.\', \'Wallenberg Center for Molecular Medicine, Umeå University, Umeå, Sweden.\', \'Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.\', \'Department of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden.\', \'Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.\', \'Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.\', \'Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.\', \'Division of Urological Cancers, Department of Translational Medicine, Lund University, Malmö, Sweden.\', \'Department of Translational Medicine, Infectious Diseases Research Unit, Lund University, Malmö, Sweden.\', \'Department of Infectious Diseases, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.\', \'Department of Urology/Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 405 30, Gothenburg, Sweden. Andreas.josefsson@umu.se.\', \'Department of Surgical and Perioperative Sciences, Urology & Andrology, Umeå University, 901 87, Umeå, Sweden. Andreas.josefsson@umu.se.\', \'Wallenberg Center for Molecular Medicine, Umeå University, Umeå, Sweden. Andreas.josefsson@umu.se.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-021-05137-4
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 33726804
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
?:title
  • COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all